Topics

vaccine systemic and virological concerns

vaccines
A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
A review of neurological side effects of COVID-19 vaccination
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Anaphylaxis-Induced Acute Coronary Syndrome Following Covid-19 mRNA-LNP Vaccination: Mechanisms and Therapeutic Approaches
Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections
CDC REMOVES Their Claim That mRNA & Spike Protein "Do Not Last Long In The Body”
Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May – November 2021
COVID-19 Vaccine: Critical Questions with Complicated Answers
Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019
Doctors and Scientists Write to the European Medicines Agency, Warning of COVID-19 Vaccine Dangers for a Third Time
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients
Expert testimony of Dr. Christina Parks, PhD
Fauci on Antibody Dependent Enhancement (ADE)
FDA Briefing Document - Moderna COVID-19 Vaccine
FDA Briefing Document: Vaccines and Related Biological Products Advisory Committee Meeting
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease
Interview excerpt with Luc Montagnier (2008 Nobel Prize in Medicine)
Interview with Dr. Robert Malone, inventor of some important mRNA-vaccine technology
Letter to U.S. Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee in response to “Request for Comments related to consideration of vaccines against SARS-CoV-2”
Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
Open Letter and Notice of Liability from Doctors and Scientists to the EMA and the Members of the European Parliament Regarding COVID-19 Vaccination
Open Letter to the World Health Organization
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
Review of COVID-19 Vaccines and the Risk of Chronic Adverse Events Including Neurological Degeneration
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
SARS-CoV-2 S1 Protein Persistence in SARS-CoV-2 Negative Post-Vaccination Individuals with Long COVID/ PASC-Like Symptoms
SARS-CoV-2 Spike Protein and Lung Vascular Cells
SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines
SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2
SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia
Science Committee hearing: Testimony of Dr. Peter Hotez
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease
The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
Understanding mRNA COVID-19 Vaccines
Viral-Induced Enhanced Disease Illness
907